The Institute of Cancer Research, London, is urging NHS-England, NICE and pharmaceutical company AstraZeneca to continue discussions after the disappointing decision not to recommend targeted drug olaparib for women with early-stage, high-risk, inherited breast cancer.

Scientists have discovered the key role of a series of proteins in the survival of some triple negative breast cancers.

Researchers perform a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery - the findings could help tailor pre-surgical treatment.